Web Desc
Antibody-Based Therapeutics for Cancer
Organizer(s): Louis M. Weiner and Paul Carter
Date: February 17 - 22, 2005
Location: Hilton Santa Fe Historic Plaza Hotel, Santa Fe, NM, USA
Sponsored by Genentech, Inc. and The Director's Fund
For important information on the coronavirus, please click here
Summary of Meeting:
Monoclonal antibodies have emerged as increasingly important therapeutic vehicles for the treatment of cancer and other human diseases. Selected un-conjugated antibodies can exert clinically meaningful anti-tumor effects in important cancers such as breast cancer and lymphoma. The mechanisms underlying these exciting results remain to be elucidated, but most likely include the induction of host immune responses and the perturbation of signaling through growth factor receptors. Antibody conjugates have been used to deliver toxic principles such as radioactive particles, chemotherapy agents and catalytic toxins with increasing success in defined clinical settings. Advances in antibody engineering have permitted the systematic evaluation of structural manipulation on targeting and efficacy. Antibodies with novel specificities can be isolated with increasing ease from naive and immunized phage display libraries. Major challenges in this rapidly evolving field include the development of improved means for identifying new functional targets for antibody perturbation.
Discounted Abstract Deadline: October 18 2004
Discounted Registration Deadline: December 17 2004
We gratefully acknowledge additional support for this conference from:

Bayer USA Foundation
Genentech, Inc.Novartis Institutes for BioMedical ResearchSeattle Genetics, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.

Seattle Genetics, Inc.

Xencor, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13-CA112789-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Thursday, February 17 | 3:00PM - 7:30PM
Registration
Room: Promenade


Thursday, February 17 | 6:30PM - 7:30PM
Refreshments
Room: Promenade


Thursday, February 17 | 7:30PM - 8:30PM
Keynote Address
Room: Mesa Ballroom

Speaker 1 of 1
Ronald Levy, Stanford University, USA
Antibody Therapy for Lymphoma - Progress and Prospects


Friday, February 18 | 7:00AM - 8:00AM
Breakfast
Room: Chamisa


Friday, February 18 | 8:00AM - 11:00AM
Antibody - Fc Receptor Interactions and Manipulation
Room: Mesa Ballroom

Speaker 1 of 4
E. Sally Ward, University of Texas Southwestern Medical Center, USA
FcRn as a Regulator of IgG trafficking: from Protein Engineering to Single Molecule Imaging

Friday, February 18 | 8:00AM - 11:00AM
Antibody - Fc Receptor Interactions and Manipulation
Room: Mesa Ballroom

Speaker 2 of 4
Raphael Clynes, Xencor, Inc., USA
Fc Receptors Link Antibody and T Cell Effector Responses in Tumor Immunity and Autoimmunity

Friday, February 18 | 8:00AM - 11:00AM
Antibody - Fc Receptor Interactions and Manipulation
Room: Mesa Ballroom

Speaker 3 of 4
Bassil I. Dahiyat, Xencor, USA
Fc Domain Engineering to Improve Antibody Function

Friday, February 18 | 8:00AM - 11:00AM
Antibody - Fc Receptor Interactions and Manipulation
Room: Mesa Ballroom

Speaker 4 of 4
* Louis M. Weiner, Georgetown University Medical Center, USA
Manipulation of Antibody Effector Function

Friday, February 18 | 9:20AM - 9:40AM
Coffee Break
Room: Promenade


Friday, February 18 | 11:00AM - 1:00PM
Poster Setup
Room: Ortiz


Friday, February 18 | 1:00PM - 10:00PM
Poster Viewing
Room: Ortiz


Friday, February 18 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Promenade


Friday, February 18 | 5:00PM - 7:15PM
Antibody Manipulation of Target Function
Room: Mesa Ballroom

Speaker 1 of 4
* Martin J. Glennie, University of Southampton, UK
Making CD20 mAb More Effective

Friday, February 18 | 5:00PM - 7:15PM
Antibody Manipulation of Target Function
Room: Mesa Ballroom

Speaker 2 of 4
José Baselga, Memorial Sloan-Kettering Cancer Center, USA
Mechanisms of Action of EGFr-Inhibitory Antibodies and Small Molecules

Friday, February 18 | 5:00PM - 7:15PM
Antibody Manipulation of Target Function
Room: Mesa Ballroom

Speaker 3 of 4
Mark X. Sliwkowski, Genentech, Inc., USA
Therapeutic Approaches to Targeting ErbB2/HER2 in Solid Tumors

Friday, February 18 | 5:00PM - 7:15PM
Antibody Manipulation of Target Function
Room: Mesa Ballroom

Speaker 4 of 4
Mark D. Pegram, Stanford Cancer Institute, USA
Phase I Combined Biological Therapy of Breast Cancer Using Two Humanized Monoclonal Antibodies Directed against HER2 Proto-Oncogene and Vascular Endothelial Growth Factor (VEGF)

Friday, February 18 | 7:15PM - 8:15PM
Social Hour
Room: Chamisa/Ortiz


Friday, February 18 | 7:30PM - 10:00PM
Poster Session 1
Room: Chamisa/Ortiz


Saturday, February 19 | 7:00AM - 8:00AM
Breakfast
Room: Chamisa


Saturday, February 19 | 8:00AM - 11:00AM
Novel Antibody Structures
Room: Mesa Ballroom

Speaker 1 of 4
Peter J. Hudson, Avipep Pty Ltd, Australia
Design and Applications of Multivalent Antibody-Like Molecules

Saturday, February 19 | 8:00AM - 11:00AM
Novel Antibody Structures
Room: Mesa Ballroom

Speaker 2 of 4
Annemarie Honegger, University of Zürich, Switzerland
Biophysical Properties of Antibody Fragments: Importance for Applications

Saturday, February 19 | 8:00AM - 11:00AM
Novel Antibody Structures
Room: Mesa Ballroom

Speaker 3 of 4
Hilde Revets, Ablynx, Belgium

NanobodiesTM: A Novel Class of Antibody Fragments for Cancer Therapy


Saturday, February 19 | 8:00AM - 11:00AM
Novel Antibody Structures
Room: Mesa Ballroom

Speaker 4 of 4
Carlos F. Barbas III, The Scripps Research Institute, USA
Chemical Approaches to Cancer Immunotherapy

Saturday, February 19 | 9:20AM - 9:40AM
Coffee Break
Room: Promenade


Saturday, February 19 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Promenade


Saturday, February 19 | 5:00PM - 7:00PM
Radioimmunodetection and Radioimmunotherapy
Room: Mesa Ballroom

Speaker 1 of 3
* Anna M. Wu, University of California, Los Angeles, USA
Tailoring Antibody Fragments for Radionuclide Delivery


Saturday, February 19 | 5:00PM - 7:00PM
Radioimmunodetection and Radioimmunotherapy
Room: Mesa Ballroom

Speaker 2 of 3
Gregory P. Adams, Sesen Bio, USA
Radioimmunotherapy of Solid Tumors with anti-HER2 Diabodies - Promise and Problems

Saturday, February 19 | 5:00PM - 7:00PM
Radioimmunodetection and Radioimmunotherapy
Room: Mesa Ballroom

Speaker 3 of 3
Robert M. Sharkey, Garden State Cancer Center, USA
Pretargeting of Radionuclides for Improved Imaging and Therapy of Cancer

Saturday, February 19 | 7:00PM - 8:00PM
Social Hour
Room: Chamisa/Ortiz


Sunday, February 20 | 7:00AM - 8:00AM
Breakfast
Room: Chamisa


Sunday, February 20 | 8:00AM - 11:00AM
Advances in Antibody Engineering
Room: Mesa Ballroom

Speaker 1 of 4
Jan E. Schnitzer, Proteogenomics Research Institute for Systems Medicine (PRISM), USA
Immunotargeting Endothelial Caveolae To Improve Penetration, Imaging and Therapy of Solid Tumors

Sunday, February 20 | 8:00AM - 11:00AM
Advances in Antibody Engineering
Room: Mesa Ballroom

Speaker 2 of 4
Wayne A. Marasco, Dana Farber Cancer Institute, USA
Potential Use of Human Monoclonal Antibodies Against CXCR4 for Adjuvant Breast Cancer Therapy

Sunday, February 20 | 8:00AM - 11:00AM
Advances in Antibody Engineering
Room: Mesa Ballroom

Speaker 3 of 4
* James D. Marks, University of California, San Francisco, USA
Tumor Cell Bindings and Internalizing Antibodies from Phage Libraries

Sunday, February 20 | 8:00AM - 11:00AM
Advances in Antibody Engineering
Room: Mesa Ballroom

Speaker 4 of 4
Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Tumor Targeting Theory and Experiment

Sunday, February 20 | 9:20AM - 9:40AM
Coffee Break
Room: Promenade


Sunday, February 20 | 11:00AM - 1:00PM
Poster Setup
Room: Ortiz


Sunday, February 20 | 1:00PM - 10:00PM
Poster Viewing
Room: Ortiz


Sunday, February 20 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Promenade


Sunday, February 20 | 5:00PM - 7:00PM
Workshop: Oral Presentations
Room: Mesa Ballroom

Speaker 1 of 6
* Peter D. Senter, Seattle Genetics Inc., USA

Sunday, February 20 | 5:00PM - 7:00PM
Workshop: Oral Presentations
Room: Mesa Ballroom

Speaker 2 of 6
Jan P. H. Depta, Avidex Limited, UK
Redirection of Cytotoxic T Cell Responses to MHC Class I Restricted Cancer Antigens using High Affinity T Cell Receptor-Superantigen Fusion Proteins

Sunday, February 20 | 5:00PM - 7:00PM
Workshop: Oral Presentations
Room: Mesa Ballroom

Speaker 3 of 6
Veronika Rayzman, CSL Limited, Australia
Engineering and Molecular Characterisation of Chimeric Monoclonal Antibody 806 (ch806) for Targeted Immunotherapy of Tumours Expressing de2-7 EGFR or Amplified EGFR

Sunday, February 20 | 5:00PM - 7:00PM
Workshop: Oral Presentations
Room: Mesa Ballroom

Speaker 4 of 6
Robin C. Humphreys, Human Genome Sciences, USA
An Agonistic, Human TRAIL Receptor 2 Monoclonal Antibody, HGS-TR2J, Stimulates the TRAIL Receptor Signaling Pathway, Actively Induces Apoptosis, Tumor Regression and Growth Inhibition in Xenograft Tumor Models

Sunday, February 20 | 5:00PM - 7:00PM
Workshop: Oral Presentations
Room: Mesa Ballroom

Speaker 5 of 6
Mark S. Dennis, Denali Therapeutics, USA
Tumor Targeting and Efficacy of AB.Fab Conjugates

Sunday, February 20 | 5:00PM - 7:00PM
Workshop: Oral Presentations
Room: Mesa Ballroom

Speaker 6 of 6
Pablo Umaña, Roche Innovation Center Zürich, Switzerland
Therapeutic Glycoengineered Antibodies with Higher Binding Affinity to FcgammaRIII Receptor and Increased ADCC: Comparison to Fc Polypeptide Variants and New Mechanistic Findings

Sunday, February 20 | 7:00PM - 8:00PM
Social Hour
Room: Chamisa/Ortiz


Sunday, February 20 | 7:30PM - 10:00PM
Poster Session 2
Room: Chamisa/Ortiz


Monday, February 21 | 7:00AM - 8:00AM
Breakfast
Room: Chamisa


Monday, February 21 | 8:00AM - 11:00AM
Antibodies as Effector Molecules
Room: Mesa Ballroom

Speaker 1 of 4
* Paul Carter, Genentech, Inc., USA
Redesigning Antibodies for Drug Conjugation for Cancer Therapy

Monday, February 21 | 8:00AM - 11:00AM
Antibodies as Effector Molecules
Room: Mesa Ballroom

Speaker 2 of 4
Sherie L. Morrison, University of California, Los Angeles, USA
Antibody Fusion Proteins for Cancer Immunotherapy

Monday, February 21 | 8:00AM - 11:00AM
Antibodies as Effector Molecules
Room: Mesa Ballroom

Speaker 3 of 4
Richard H.J. Begent, University College London, UK
Antibody-Directed Enzyme Prodrug Therapy

Monday, February 21 | 8:00AM - 11:00AM
Antibodies as Effector Molecules
Room: Mesa Ballroom

Speaker 4 of 4
Dario Neri, ETH Zürich, Switzerland
Antibody-Based Targeting of Tumor Neo-Vasculature

Monday, February 21 | 9:20AM - 9:40AM
Coffee Break
Room: Promenade


Monday, February 21 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Promenade


Monday, February 21 | 5:00PM - 7:00PM
Clinical Updates and New Directions
Room: Mesa A-B

Speaker 1 of 3
Jan van de Winkel, Genmab, Netherlands
Novel Human Antibodies Targeting CD20

Monday, February 21 | 5:00PM - 7:00PM
Clinical Updates and New Directions
Room: Mesa A-B

Speaker 2 of 3
* George J. Weiner, University of Iowa, USA
Monoclonal Antibody Therapy and NK Activation

Monday, February 21 | 5:00PM - 7:00PM
Clinical Updates and New Directions
Room: Mesa A-B

Speaker 3 of 3
Soldano Ferrone, University of Pittsburgh, USA
Structural Basis of Human High Molecular Weight-Melanoma Associated Antigen Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23

Monday, February 21 | 7:00PM - 8:00PM
Social Hour
Room: Promenade


Monday, February 21 | 8:00PM - 11:00PM
Entertainment
Room: Mesa Ballroom


Monday, February 21 | 8:00PM - 11:00PM
Cash Bar
Room: Mesa Ballroom


Tuesday, February 22 | 10:21AM - 10:21AM
Departure


*Session Chair
†Invited, not yet responded.